Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 62, Issue , 2015, Pages 51-60

  Crowley, Nicole A ^a,b   Kash, Thomas L ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Anxiety; Circuitry; Dynorphin; KOR; Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; KAPPA OPIATE RECEPTOR;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG DEPENDENCE; DRUG TARGETING; HIPPOCAMPUS; HUMAN; NERVE CELL NETWORK; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VENTRAL TEGMENTUM; ANIMAL; ANXIETY DISORDERS; BRAIN; DEPRESSIVE DISORDER; DRUG EFFECTS; METABOLISM; NERVE TRACT; SUBSTANCE-RELATED DISORDERS;

ANIMALS; ANXIETY DISORDERS; BRAIN; DEPRESSIVE DISORDER; HUMANS; NEURAL PATHWAYS; RECEPTORS, OPIOID, KAPPA; SUBSTANCE-RELATED DISORDERS;

EID: 84937969532     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.01.001     Document Type: Article

References (168)

1. Al-Hasani R., McCall J.G., Bruchas M.R. Exposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preference. Front Pharmacol 2013, 4:96.
2. Asensio V.J., Miralles A., Garcia-Sevilla J.A. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol 2006, 539:49-56.
3. Bals-Kubik R., Ableitner A., Herz A., Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 1993, 264:489-495.
4. Beardsley P.M., Howard J.L., Shelton K.L., Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 2005, 183:118-126.
5. Belcheva M.M., Clark A.L., Haas P.D., Serna J.S., Hahn J.W., et al. Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 2005, 280:27662-27669.
6. Berger A.L., Williams A.M., McGinnis M.M., Walker B.M. Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2013, 38:647-654.
7. Berube P., Laforest S., Bhatnagar S., Drolet G. Enkephalin and dynorphin mRNA expression are associated with resilience or vulnerability to chronic social defeat stress. Physiol Behav 2013, 122:237-245.
8. Bidlack J.M. Mixed kappa/mu partial opioid agonists as potential treatments for cocaine dependence. Adv Pharmacol (San Diego Calif) 2014, 69:387-418.
9. Bilkei-Gorzo A., Racz I., Michel K., Mauer D., Zimmer A., et al. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008, 33:425-436.
10. Bilkei-Gorzo A., Erk S., Schurmann B., Mauer D., Michel K., et al. Dynorphins regulate fear memory: from mice to men. J Neurosci Off J Soc Neurosci 2012, 32:9335-9343.
11. Bilkei-Gorzo A., Mauer D., Michel K., Zimmer A. Dynorphins regulate the strength of social memory. Neuropharmacology 2014, 77:406-413.
12. Bortolato M., Solbrig M.V. The price of seizure control: dynorphins in interictal and postictal psychosis. Psychiatry Res 2007, 151:139-143.
13. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., et al. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 2008, 63:286-292.
14. Braida D., Capurro V., Zani A., Rubino T., Vigano D., et al. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 2009, 157:844-853.
15. Bruchas M., Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) 2010, 210:137-147.
16. Bruchas M.R., Macey T.A., Lowe J.D., Chavkin C. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 2006, 281:18081-18089.
17. Bruchas M.R., Land B.B., Aita M., Xu M., Barot S.K., et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci Off J Soc Neurosci 2007, 27:11614-11623.
18. Bruchas M.R., Xu M., Chavkin C. Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport 2008, 19:1417-1422.
19. Bruchas M.R., Land B.B., Lemos J.C., Chavkin C. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One 2009, 4:e8528.
20. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 2010, 1314:44-55.
21. Bruchas M.R., Schindler A.G., Shankar H., Messinger D.I., Miyatake M., et al. Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011, 71:498-511.
22. Carr G.V., Bangasser D.A., Bethea T., Young M., Valentino R.J., Lucki I. Antidepressant-like effects of [kappa]-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2009, 35:752-763.
23. Carr G.V., Bangasser D.A., Bethea T., Young M., Valentino R.J., Lucki I. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2010, 35:752-763.
24. Cashman J.R., Azar M.R. Potent inhibition of alcohol self-administration in alcohol-preferring rats by a kappa-opioid receptor antagonist. J Pharmacol Exp Ther 2014, 350:171-180.
25. Castagné V., Moser P., Roux S., Porsolt R.D. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice in Current Protocols in Neuroscience 2001, John Wiley & Sons, Inc.
26. Castro D.C., Berridge K.C. Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness "liking" and "wanting". J Neurosci Off J Soc Neurosci 2014, 34:4239-4250.
27. Chartoff E.H., Papadopoulou M., MacDonald M.L., Parsegian A., Potter D., et al. Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 2009, 75:704-712.
28. Chartoff E., Sawyer A., Rachlin A., Potter D., Pliakas A., Carlezon W.A. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62:167-176.
29. Chavkin C. Dynorphins are endogenous opioid peptides released from granule cells to act neurohumorly and inhibit excitatory neurotransmission in the hippocampus. Prog Brain Res 2000, 125:363-367.
30. Chavkin C., Goldstein A. Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus. Nature 1981, 291:591-593.
31. Chavkin C., Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc Natl Acad Sci U S A 1981, 78:6543-6547.
32. Chavkin C., James I.F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science (New York, NY) 1982, 215:413-415.
33. Chavkin C., Shoemaker W.J., McGinty J.F., Bayon A., Bloom F.E. Characterization of the prodynorphin and proenkephalin neuropeptide systems in rat hippocampus. J Neurosci Off J Soc Neurosci 1985, 5:808-816.
34. Chefer V.I., Shippenberg T.S. Paradoxical effects of prodynorphin gene deletion on basal and cocaine-evoked dopaminergic neurotransmission in the nucleus accumbens. Eur J Neurosci 2006, 23:229-238.
35. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci Off J Soc Neurosci 2005, 25:5029-5037.
36. Chefer V.I., Backman C.M., Gigante E.D., Shippenberg T.S. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2013, 38:2623-2631.
37. Clynen E., Swijsen A., Raijmakers M., Hoogland G., Rigo J.M. Neuropeptides as targets for the development of anticonvulsant drugs. Mol Neurobiol 2014, (Epub 2014 Apr 6). 10.1007/s12035-014-8669-x.
38. Contarino A., Papaleo F. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci U S A 2005, 102:18649-18654.
39. Cupic B., Stefulj J., Zapletal E., Matosic A., Bordukalo-Niksic T., et al. Opioid system genes in alcoholism: a case-control study in Croatian population. Neuropeptides 2013, 47:315-319.
40. D'Addario C., Caputi F.F., Rimondini R., Gandolfi O., Del Borrello E., et al. Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol 2013, 18:425-433.
41. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988, 244:1067-1080.
42. Diaz-Cenzano E., Gaztanaga M., Gabriela Chotro M. Exposure to ethanol on prenatal days 19-20 increases ethanol intake and palatability in the infant rat: involvement of kappa and mu opioid receptors. Dev Psychobiol 2014, 56:1167-1178.
43. Dobolyi A., Kekesi K.A., Juhasz G., Szekely A.D., Lovas G., Kovacs Z. Receptors of peptides as therapeutic targets in epilepsy research. Curr Med Chem 2014, 21:764-787.
44. Drake C.T., Terman G.W., Simmons M.L., Milner T.A., Kunkel D.D., et al. Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J Neurosci Off J Soc Neurosci 1994, 14:3736-3750.
45. Ehrich J.M., Phillips P.E. Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2014, 39:3036-3048.
46. Endoh T., Matsuura H., Tanaka C., Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 1992, 316:30-42.
47. Evans S.J., Searcy B.T., Moore F.L. A subset of kappa opioid ligands bind to the membrane glucocorticoid receptor in an amphibian brain. Endocrinology 2000, 141:2294-2300.
48. Faisal M., Waseem D., Ismatullah H., Taqi M.M. A molecular prospective provides new insights into implication of PDYN and OPRK1 genes in alcohol dependence. Comput Biol Med 2014, 53c:250-257.
49. Freeman K.B., Naylor J.E., Prisinzano T.E., Woolverton W.L. Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) 2014, 231:2751-2758.
50. Fu Y., Neugebauer V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. J Neurosci Off J Soc Neurosci 2008, 28:3861-3876.
51. Funada M., Suzuki T., Narita M., Misawa M., Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 1993, 32:1315-1323.
52. Funk D., Coen K., Le A.D. The role of kappa opioid receptors in stress-induced reinstatement of alcohol seeking in rats. Brain Behav 2014, 4:356-367.
53. Gehrke B.J., Chefer V.I., Shippenberg T.S. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) 2008, 197:509-517.
54. Gieryk A., Ziolkowska B., Solecki W., Kubik J., Przewlocki R. Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity. Psychopharmacology (Berl) 2010, 208:291-300.
55. Gilpin N.W., Roberto M., Koob G.F., Schweitzer P. Kappa opioid receptor activation decreases inhibitory transmission and antagonizes alcohol effects in rat central amygdala. Neuropharmacology 2014, 77:294-302.
56. Glick S.D., Maisonneuve I.M., Raucci J., Sydney A. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 1995, 681:147-152.
57. Graziane N.M., Polter A.M., Briand L.A., Pierce R.C., Kauer J.A. Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity. Neuron 2013, 77:942-954.
58. Gysling K. Relevance of both type-1 and type-2 corticotropin releasing factor receptors in stress-induced relapse to cocaine seeking behaviour. Biochem Pharmacol 2012, 83:1-5.
59. Hahn J.W., Jagwani S., Kim E., Rendell V.R., He J., et al. Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases. J Neurochem 2010, 112:1431-1441.
60. Hasebe K., Kawai K., Suzuki T., Kawamura K., Tanaka T., et al. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 2004, 1025:404-413.
61. Heilig M., Schank J.R. Kappa-opioid receptor antagonism: a mechanism for treatment of relief drinking?. Biol Psychiatry 2014, 75:750-751.
62. Henderson-Redmond A., Czachowski C. Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. Psychopharmacology (Berl) 2014, 231:4309-4321.
63. Hjelmstad G.O., Fields H.L. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol 2003, 89:2389-2395.
64. Huge V., Rammes G., Beyer A., Zieglgansberger W., Azad S.C. Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur J Pain (Lond Engl) 2009, 13:124-129.
65. Iyengar S., Kim H.S., Wood P.L. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J Pharmacol Exp Ther 1986, 238:429-436.
66. Iyengar S., Kim H.S., Wood P.L. μ-, δ-, κ- and ε-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res 1987, 435:220-226.
67. Kallupi M., Wee S., Edwards S., Whitfield T.W., Oleata C.S., et al. Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction. Biol Psychiatry 2013, 74:520-528.
68. Kanemitsu Y., Hosoi M., Zhu P.J., Weight F.F., Peoples R.W., et al. Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism. Mol Cell Neurosci 2003, 24:525-537.
69. Kang-Park M., Kieffer B.L., Roberts A.J., Siggins G.R., Moore S.D. Kappa-opioid receptors in the central amygdala regulate ethanol actions at presynaptic GABAergic sites. J Pharmacol Exp Ther 2013, 346:130-137.
70. Kaster M.P., Budni J., Santos A.R., Rodrigues A.L. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. Eur J Pharmacol 2007, 576:91-98.
71. Kissler J.L., Sirohi S., Reis D.J., Jansen H.T., Quock R.M., et al. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry 2014, 75:774-782.
72. Kivell B., Uzelac Z., Sundaramurthy S., Rajamanickam J., Ewald A., et al. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 2014, 86c:228-240.
73. Kivell B., Uzelac Z., Sundaramurthy S., Rajamanickam J., Ewald A., et al. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 2014, 86:228-240.
74. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., Carlezon W.A. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007, 323:838-845.
75. Knoll A.T., Muschamp J.W., Sillivan S.E., Ferguson D., Dietz D.M., et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 2011, 70:425-433.
76. Koob G.F. Stress, corticotropin-releasing factor, and drug addiction. Ann N Y Acad Sci 1999, 897:27-45.
77. Koob G.F. Addiction is a reward deficit and stress surfeit disorder. Front Psychiatry 2013, 4:72.
78. Kovacs K.M., Szakall I., O'Brien D., Wang R., Vinod K.Y., et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res 2005, 29:730-738.
79. Kuzmin A., Chefer V., Bazov I., Meis J., Ogren S.O., et al. Upregulated dynorphin opioid peptides mediate alcohol-induced learning and memory impairment. Transl Psychiatry 2013, 3:e310.
80. Lam M.P., Gianoulakis C. Effects of corticotropin-releasing hormone receptor antagonists on the ethanol-induced increase of dynorphin A1-8 release in the rat central amygdala. Alcohol (Fayetteville, NY) 2011, 45:621-630.
81. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci Off J Soc Neurosci 2008, 28:407-414.
82. Land B.B., Bruchas M.R., Schattauer S., Giardino W.J., Aita M., et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci 2009, 106:19168-19173.
83. Le A., Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol Ther 2002, 94:137-156.
84. Leeman R.F., Heilig M., Cunningham C.L., Stephens D.N., Duka T., O'Malley S.S. Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. Addict Biol 2010, 15:109-124.
85. Lemos J.C., Roth C.A., Messinger D.I., Gill H.K., Phillips P.E., Chavkin C. Repeated stress dysregulates kappa-opioid receptor signaling in the dorsal raphe through a p38alpha MAPK-dependent mechanism. J Neurosci Off J Soc Neurosci 2012, 32:12325-12336.
86. Li Z., Zhang H. Analyzing interaction of mu-, delta- and kappa-opioid receptor gene variants on alcohol or drug dependence using a pattern discovery-based method. J Addict Res Ther 2013, (Suppl. 7: 007).
87. Li J.-G., Luo L.-Y., Krupnick J.G., Benovic J.L., Liu-Chen L.-Y. U50,488H-induced internalization of the human κ opioid receptor involves a β-arrestin- and dynamin-dependent mechanism: κ receptor internalization is not required for mitogen-activated protein kinase activation. J Biol Chem 1999, 274:12087-12094.
88. Li C., Pleil K.E., Stamatakis A.M., Busan S., Vong L., et al. Presynaptic inhibition of gamma-aminobutyric acid release in the bed nucleus of the stria terminalis by kappa opioid receptor signaling. Biol Psychiatry 2012, 71:725-732.
89. Loacker S., Sayyah M., Wittmann W., Herzog H., Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain J Neurol 2007, 130:1017-1028.
90. Logrip M.L., Janak P.H., Ron D. Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake. FASEB J 2008 Jul, 22(7):2393-2404. (Epub 2008 Feb 29). 10.1096/fj.07-099135.
91. Logrip M.L., Janak P.H., Ron D. Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H. Alcohol 2009 Aug, 43(5):359-365. 10.1016/j.alcohol.2009.05.001.
92. Lowe S.L., Wong C.J., Witcher J., Gonzales C.R., Dickinson G.L., et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol 2014, 54:968-978.
93. Lowery-Gionta E.G., Marcinkiewcz C.A., Kash T.L. Functional alterations in the dorsal raphe nucleus following acute and chronic ethanol exposure. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2014, 40:590-600.
94. Lucas L.R., Dragisic T., Duwaerts C.C., Swiatkowski M., Suzuki H. Effects of recovery from immobilization stress on striatal preprodynorphin- and kappa opioid receptor-mRNA levels of the male rat. Physiol Behav 2011, 104:972-980.
95. Madamba S.G., Schweitzer P., Siggins G.R. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. J Neurophysiol 1999, 82:1768-1775.
96. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003, 305:323-330.
97. Maier S.F., Watkins L.R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 2005, 29:829-841.
98. Manzoni O.J., Williams J.T. Presynaptic regulation of glutamate release in the ventral tegmental area during morphine withdrawal. J Neurosci Off J Soc Neurosci 1999, 19:6629-6636.
99. Marchant N.J., Densmore V.S., Osborne P.B. Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division. J Comp Neurol 2007, 504:702-715.
100. Margolis E.B., Hjelmstad G.O., Bonci A., Fields H.L. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci Off J Soc Neurosci 2003, 23:9981-9986.
101. Margolis E.B., Hjelmstad G.O., Bonci A., Fields H.L. Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons. J Neurophysiol 2005, 93:3086-3093.
102. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., Fields H.L. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A 2006, 103:2938-2942.
103. Margolis E.B., Mitchell J.M., Ishikawa J., Hjelmstad G.O., Fields H.L. Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. J Neurosci Off J Soc Neurosci 2008, 28:8908-8913.
104. Massachusetts General Hospital Proof-of-Concept Trial of LY2456302 Augmentation of Antidepressant Therapy in Treatment-resistant Depression 2013 30 July.
105. McDermott C.M., Schrader L.A. Activation of kappa opioid receptors increases intrinsic excitability of dentate gyrus granule cells. J Physiol 2011, 589:3517-3532.
106. McLaughlin J.P., Marton-Popovici M., Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci Off J Soc Neurosci 2003, 23:5674-5683.
107. McLaughlin J.P., Land B.B., Li S., Pintar J.E., Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2006, 31:787-794.
108. McLennan G.P., Kiss A., Miyatake M., Belcheva M.M., Chambers K.T., et al. Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem 2008, 107:1753-1765.
109. Meister B., Villar M.J., Ceccatelli S., Hokfelt T. Localization of chemical messengers in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei: an immunohistochemical study using experimental manipulations. Neuroscience 1990, 37:603-633.
110. Morales M., Anderson R.I., Spear L.P., Varlinskaya E.I. Effects of the kappa opioid receptor antagonist, nor-binaltorphimine, on ethanol intake: impact of age and sex. Dev Psychobiol 2014, 56:700-712.
111. Mu P., Neumann P.A., Panksepp J., Schluter O.M., Dong Y. Exposure to cocaine alters dynorphin-mediated regulation of excitatory synaptic transmission in nucleus accumbens neurons. Biol Psychiatry 2011, 69:228-235.
112. Muschamp J.W., Hollander J.A., Thompson J.L., Voren G., Hassinger L.C., et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A 2014, 111:E1648-E1655.
113. Nascimento A.I., Ferreira H.S., Saraiva R.M., Almeida T.S., Fregoneze J.B. Central kappa opioid receptors modulate salt appetite in rats. Physiol Behav 2012, 106:506-514.
114. Nizhnikov M.E., Pautassi R.M., Carter J.M., Landin J.D., Varlinskaya E.I., et al. Brief prenatal ethanol exposure alters behavioral sensitivity to the kappa opioid receptor agonist (U62,066E) and antagonist (Nor-BNI) and reduces kappa opioid receptor expression. Alcohol Clin Exp Res 2014, 38:1630-1638.
115. Nutt D.J. The role of the opioid system in alcohol dependence. J Psychopharmacol (Oxf Engl) 2014, 28:8-22.
116. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986, 24:525-529.
117. Peters M.F., Zacco A., Gordon J., Maciag C.M., Litwin L.C., et al. Identification of short-acting kappa-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 2011, 661:27-34.
118. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science (New York, NY) 1986, 233:774-776.
119. Pinnock R.D. Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitro. Brain Res 1992, 583:237-246.
120. Pirker S., Gasser E., Czech T., Baumgartner C., Schuh E., et al. Dynamic up-regulation of prodynorphin transcription in temporal lobe epilepsy. Hippocampus 2009, 19:1051-1054.
121. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
122. Potter D.N., Damez-Werno D., Carlezon W.A., Cohen B.M., Chartoff E.H. Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 2011, 70:744-753.
123. Poulin J.F., Arbour D., Laforest S., Drolet G. Neuroanatomical characterization of endogenous opioids in the bed nucleus of the stria terminalis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1356-1365.
124. Privette T.H., Terrian D.M. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology (Berl) 1995, 118:444-450.
125. Racz I., Markert A., Mauer D., Stoffel-Wagner B., Zimmer A. Long-term ethanol effects on acute stress responses: modulation by dynorphin. Addict Biol 2013, 18:678-688.
126. Reindl J.D., Rowan K., Carey A.N., Peng X., Neumeyer J.L., McLaughlin J.P. Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology 2008, 81:229-235.
127. Reyes B.A., Drolet G., Van Bockstaele E.J. Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents. J Comp Neurol 2008, 508:663-675.
128. Rittase W.B., Dong Y., Barksdale D., Galdzicki Z., Bausch S.B. Dynorphin up-regulation in the dentate granule cell mossy fiber pathway following chronic inhibition of GluN2B-containing NMDAR is associated with increased CREB (Ser 133) phosphorylation, but is independent of BDNF/TrkB signaling pathways. Mol Cell Neurosci 2014, 60:63-71.
129. Rocha L., Maidment N.T. Opioid peptide release in the rat hippocampus after kainic acid-induced status epilepticus. Hippocampus 2003, 13:472-480.
130. Roth K.A., Weber E., Barchas J.D., Chang D., Chang J.K. Immunoreactive dynorphin-(1-8) and corticotropin-releasing factor in subpopulation of hypothalamic neurons. Science (New York, NY) 1983, 219:189-191.
131. RTI-International First in Humans Study of JDTic 2012, May 9.
132. Schank J.R., Goldstein A.L., Rowe K.E., King C.E., Marusich J.A., et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol 2012, 17:634-647.
133. Schlosburg J.E., Whitfield T.W., Park P.E., Crawford E.F., George O., et al. Long-term antagonism of kappa opioid receptors prevents escalation of and increased motivation for heroin intake. J Neurosci Off J Soc Neurosci 2013, 33:19384-19392.
134. Sedki F., Eigenmann K., Gelinas J., Schouela N., Courchesne S., Shalev U. A role for kappa-, but not mu-opioid, receptor activation in acute food deprivation-induced reinstatement of heroin seeking in rats. Addict Biol 2014, 1-10.
135. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 1993, 265:53-59.
136. Shippenberg T.S., LeFevour A., Heidbreder C. Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 1996, 276:545-554.
137. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004, 90:1258-1268.
138. Solbrig M.V., Adrian R., Baratta J., Lauterborn J.C., Koob G.F. Kappa opioid control of seizures produced by a virus in an animal model. Brain J Neurol 2006, 129:642-654.
139. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 1992, 89:2046-2050.
140. Spanagel R., Almeida O.F., Bartl C., Shippenberg T.S. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology (Berl) 1994, 115:121-127.
141. Svingos A.L., Colago E.E. Kappa-opioid and NMDA glutamate receptors are differentially targeted within rat medial prefrontal cortex. Brain Res 2002, 946:262-271.
142. Svingos A.L., Chavkin C., Colago E.E., Pickel V.M. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse (New York, NY) 2001, 42:185-192.
143. Tao R., Auerbach S.B. mu-Opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res 2005, 1049:70-79.
144. Tejeda H.A., Chefer V.I., Zapata A., Shippenberg T.S. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Psychopharmacology (Berl) 2010, 210:231-240.
145. Tejeda H.A., Counotte D.S., Oh E., Ramamoorthy S., Schultz-Kuszak K.N., et al. Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2013, 38:1770-1779.
146. Thai L., Lee P.H., Ho J., Suh H., Hong J.S. Regulation of prodynorphin gene expression in the hippocampus by glucocorticoids. Brain Res Mol Brain Res 1992, 16:150-157.
147. Todtenkopf M.S., Marcus J.F., Portoghese P.S., Carlezon W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 2004, 172:463-470.
148. Tomkins D.M., Sellers E.M., Fletcher P.J. Effect of dorsal raphe injections of the GABAA agonist, muscimol, on ethanol intake and measures of intoxication in Wistar rats. Alcohol Alcohol (Oxf Oxfordshire) 1994, (Supplement 2):551-558.
149. Trifilieff P., Martinez D. Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. Front Psychiatry 2013, 4.
150. Trifilieff P., Martinez D. Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. Front Psychiatry 2013, 4:44.
151. Valdez G.R., Harshberger E. Kappa opioid regulation of anxiety-like behavior during acute ethanol withdrawal. Pharmacol Biochem Behav 2012, 102:44-47.
152. Valdez G.R., Platt D.M., Rowlett J.K., Ruedi-Bettschen D., Spealman R.D. Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms. J Pharmacol Exp Ther 2007, 323:525-533.
153. Vander Weele C.M., Porter-Stransky K.A., Mabrouk O.S., Lovic V., Singer B.F., et al. Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. Eur J Neurosci 2014, 40:3041-3054.
154. Van't Veer A., Yano J.M., Carroll F.I., Cohen B.M., Carlezon W.A. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the kappa-opioid receptor antagonist JDTic. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharm 2012, 37:2809-2816.
155. Wagner J.J., Terman G.W., Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993, 363:451-454.
156. Walker B.M., Valdez G.R., McLaughlin J.P., Bakalkin G. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol (Fayetteville, NY) 2012, 46:359-370.
157. Wan X.W., Li W.H., Huang M., You Z.D., Tan Y.X., et al. Levels of immunoreactive dynorphin A1-13 during development of morphine dependence in rats. Zhongguo Yao Li Xue Bao Acta Pharmacol Sin 1998, 19:560-563.
158. Wang S.C., Tsou H.H., Chung R.H., Chang Y.S., Fang C.P., et al. The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol 2014, 34:205-211.
159. Watanabe Y., Weiland N.G., McEwen B.S. Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus. Brain Res 1995, 680:217-225.
160. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 2010, 210:121-135.
161. Weisskopf M.G., Zalutsky R.A., Nicoll R.A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature 1993, 362:423-427.
162. Wimpey T.L., Chavkin C. Opioids activate both an inward rectifier and a novel voltage-gated potassium conductance in the hippocampal formation. Neuron 1991, 6:281-289.
163. Wright R.C., Ingenito A.J. Prevention of isolation-induced hypertension by intrahippocampal administration of a nonpeptide kappa-opioid receptor agonist. Hippocampus 2001, 11:445-451.
164. Wright R.C., Ingenito A.J. Blockade of dorsal hippocampal kappa-opioid receptors increases blood pressure in normotensive and isolation-induced hypertensive rats. Neuropeptides 2003, 37:127-132.
165. Wright R.C., McConnaughey M.M., Ingenito A.J. Decreased dynorphin levels and increased kappa opioid receptor binding in male rats with isolation-induced hypertension. Peptides 2000, 21:1881-1884.
166. Yoshizawa K., Narita M., Saeki M., Narita M., Isotani K., et al. Activation of extracellular signal-regulated kinase is critical for the discriminative stimulus effects induced by U-50,488H. Synapse (New York, NY) 2011, 65:1052-1061.
167. Zheng M.Q., Nabulsi N., Kim S.J., Tomasi G., Lin S.F., et al. Synthesis and evaluation of 11C-LY2795050 as a kappa-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med Off Publ Soc Nucl Med 2013, 54:455-463.
168. Zhou Y., Colombo G., Gessa G.L., Kreek M.J. Effects of voluntary alcohol drinking on corticotropin-releasing factor and preprodynorphin mRNA levels in the central amygdala of Sardinian alcohol-preferring rats. Neurosci Lett 2013, 554:110-114.